Actively Recruiting
Single-center Study on Outcomes of Patients with Philadelphia-negative Chronic Myeloproliferative Neoplasms Including Myelofibrosis, Polycythemia Vera, and Essential Thrombocythemia
Led by Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Updated on 2026-10-07
1190
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying chronic myeloproliferative neoplasms MPNs, a group of rare blood disorders involving abnormal growth of blood-forming stem cells. These disorders include myelofibrosis, polycythemia vera, and essential thrombocythemia, which carry risks of clotting, bleeding, and progression to acute leukemia. Due to the low occurrence rate of these diseases, this study aims to collect detailed clinical, biological, and treatment data from patients to better understand outcomes. This is an observational study collecting data over many years without testing new treatments. It includes patients diagnosed with the specified MPNs, gathering information retrospectively and prospectively at a single center. The study does not involve interventions but focuses on tracking patient health and outcomes using existing medical records and follow-up. Participants aged 16 and older with confirmed diagnoses will have their data recorded and analyzed over a long period, up to 20 years. The main outcome measured is overall survival at 20 years. The study collects clinical and biological information, monitors disease progression, and observes treatment effects as part of routine care. There is no direct treatment from the study, but participants contribute valuable information that may help improve understanding of these rare blood disorders.
CONDITIONS
Brief Title
MPNdpoint. Single-center, Retrospective, Prospective Study of the Outcome of Patients With Philadelphia-negative Chronic Myeloproliferative Neoplasms
Research Team
B
Barbara Mora, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here